Concomitant chemoradiotherapy with low-dose weekly XXXX for nonmetastatic unresectable @entity788 .

@entity1 @entity3123 @entity788 @entity390 @entity5 @entity391 @entity1398 @entity158 @entity136
BACKGROUND/AIMS: This study aimed to demonstrate the efficacy and tolerability of low-dose weekly @entity136 as a radiosensitizer in unresectable @entity788 @entity1 treated with chemoradiotherapy. METHODS: Twenty-four histologically confirmed @entity3123 @entity1 (female/male: 10/14, median age: 60) were evaluated. Seven (29%) @entity1 received @entity136 either as a single agent or in combination prior to chemoradiotherapy. Concurrent 75 mg/m2 @entity136 was infused weekly. Radiotherapy was delivered to the @entity5 and positive lymphatics with 3D-conformal radiotherapy to a total dose of 4500 cGy. Local progression-free survival, distant metastasis-free survival and overall survival were evaluated by Kaplan-Meier method. RESULTS: Median follow-up was 36 weeks. Median local progression-free survival, distant metastasis-free survival and overall survival were 22 weeks (95% confidence interval [CI]: 5-59 weeks), 19 weeks (95%CI: 6.9-31 weeks) and 36 weeks (95%CI: 28-43 weeks), respectively. All @entity1 completed radiotherapy as scheduled. Concurrent @entity136 was given fully in 58.3% of @entity1 . @entity136 was terminated in four (16.6%) @entity1 due to grade 3 @entity1398 (n=1), grade 3 @entity390 / @entity391 (n=2) or @entity1 's reluctance (n=1). @entity1 with local response and stable disease to chemoradiotherapy revealed a median survival of 39 weeks (95%CI: 30-47.9 weeks) compared to 36 weeks (95%CI: 9.7-62.2 weeks) in @entity1 with locally progressive disease (p=0.52). @entity158 was improved in 50% of @entity1 . CONCLUSIONS: Weekly low-dose radiosensitizing @entity136 is effective and safe in unresectable @entity788 @entity1 .
